Here's Why Amgen (AMGN) is a Strong Growth Stock

Zacks rates Amgen (AMGN) #3 (Hold), with a B VGM score and a B Growth Style Score, and forecasts 5% year-over-year earnings growth for the current fiscal year. Five analysts raised fiscal 2026 estimates in the past 60 days, lifting the consensus by $0.52 to $22.94 per share; Amgen’s average earnings surprise is +11.3%. The article also notes that Prolia and Xgeva lost patent exclusivity in 2025 and face biosimilar competition.

Analysis

The promotional framing overweights a screening score and a small upward estimate revision relative to the more important question: whether newer products can replace erosion in established franchises. A positive earnings surprise track record is not, by itself, evidence that forward estimates will keep rising; the cited 5% growth outlook leaves limited room for patent-related pressure to be absorbed without execution elsewhere. The useful signal is therefore not the style grade but the next sequence of product-level sales and guidance revisions.

Near term (days), this article alone is unlikely to be a durable catalyst; avoid buying on the ranking claim. Over 1–3 months, monitor quarterly guidance and analyst estimate breadth, especially whether Prolia/Xgeva erosion is accelerating and whether growth in the rest of the portfolio offsets it. Over 6–18 months, biosimilar substitution could pressure pricing and mix beyond the directly affected products, while successful launches or expanding uptake in newer therapies could support a less mature revenue base. The article supplies no product-level revenue exposure, so the net effect cannot be quantified here.

Contrarian read: the bullish case may be underpricing the replacement burden, but the negative case may also overstate the impact if newer products scale. No clear directional edge from this source alone; treat estimate revisions as a catalyst to verify, not a buy signal.

Key Decisions for Investors

• AMGN: no immediate position change on this article. Do not chase the promotional growth label; the supplied rating is Hold, and the cited estimate revisions need confirmation in company guidance and subsequent analyst updates.
• Set a 1–3 month watch: compare Prolia/Xgeva sales trends with growth elsewhere in the portfolio and track whether full-year guidance or consensus EPS revisions continue to improve. Repeated downward revisions or guidance pressure would falsify the constructive thesis; sustained upward revisions alongside evidence of product replacement would strengthen it.
• Avoid a sector pair or options trade until product-level exposure and valuation are checked. The article provides neither the revenue contribution at risk nor enough valuation context to frame an attractive risk/reward.